ArticleJournal of diabetes and metabolic disorders2026
Association between SARS-CoV-2 and diabetes: A population-based cohort study using the UK CPRD GOLD database.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Previous studies have reported contradictory findings about the possible association between SARS-CoV-2 and diabetes. We therefore conducted a cohort study to determine whether there is any association between SARS-CoV-2 infection and (i) new onset Type 1 diabetes and (ii) new onset Type 2 diabetes. Methods: We conducted a population-based cohort study on data from 01/01/2021 to 30/06/2022 using the UK Clinical Practice Research Datalink (CPRD) GOLD. In this database, the exposure cohort (Covid) was matched to the comparator cohort (No Covid), 1:1 with months as "enrolment" windows during 2021, without replacement. Large Scale Propensity Score matching was conducted using Lasso regression for variable selection. Then Poisson regression was used to examine the relationship between COVID-19 exposure and incident Type 1/Type 2 diabetes. A sensitivity analysis was performed by matching Covid cases with Negative tests. Results: 161,870 COVID-19 patients were matched to 161,870 non-Covid controls; separately, 139,419 COVID-19 patients were matched to 139,419 test-negative participants. For Type 1 diabetes, the Poisson regression analysis gave an overall risk ratio of 1.27 (0.81-1.82); and a RR of 1.13 (0.66-1.84) when matching Covid with Negative tests. For Type 2 diabetes, we obtained an overall risk ratio of 1.10 (0.98-1.23); and a RR of 1.08 (0.96-1.20) when matching Covid with Negative tests. Conclusions: We do not find evidence of an association between SARS-CoV-2 infection and new onset of Type 1 or Type 2 diabetes. However, uncertainty remains due to the small number of events, especially in the case of Type 1 diabetes. Clinical Trial Number: Not applicable. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-026-02002-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.